Simple method for the assay of linezolid in Brain Heart Infusion broth by high‐performance liquid chromatography

Li, Jian; Rayner, Craig R.; Dixson, Shirley Dorothy; Nation, Roger L.

doi:10.1002/bmc.283

Cited by 14 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If extraction recovery reached, ca. 100% after deproteinization of serum [6,9], plasma [8,11], urine [9], microdialysate [8], BHIB [10], it [15]. These last results are close to that obtained for M-HB with our method.…”

Section: Recoverysupporting

confidence: 92%

See 1 more Smart Citation

Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction

Ba¹,

Nso²,

Quentin³

et al. 2007

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Recoverysupporting

confidence: 92%

“…deproteinization [6][7][8][9][10][11] and solid-phase extraction [12][13][14], were proposed for linezolid determination in plasma, serum, urine, brain heart infusion broth (BHIB) and microdialysis samples. An on-line extraction technique [15] was also applied to serum and urine samples.…”

Section: Introductionmentioning

confidence: 99%

Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction

Ba¹,

Nso²,

Quentin³

et al. 2007

Journal of Chromatography B

View full text Add to dashboard Cite

“…Samples obtained from each treatment arm were stored at Ϫ80°C until assayed for linezolid concentrations. Linezolid concentrations in MHB were diluted with methanol and were analyzed by high-performance liquid chromatography (HPLC) using the method described by Li et al (9). Chromatographic separation was performed using a Kromasil C 18 Ciprofloxacin concentration determinations.…”

Section: Methodsmentioning

confidence: 99%

Differential Effects of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis in an In Vitro Pharmacodynamic System

Louie

VanScoy

Heine

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Bacillus anthracis causes anthrax. Ciprofloxacin is a gold standard for the treatment of anthrax. Previously, using the non-toxinproducing ⌬Sterne strain of B. anthracis, we demonstrated that linezolid was equivalent to ciprofloxacin for reducing the total (vegetative and spore) bacterial population. With ciprofloxacin therapy, the total population consisted of spores. With linezolid therapy, the population consisted primarily of vegetative bacteria. Linezolid is a protein synthesis inhibitor, while ciprofloxacin is not. Since toxins are produced only by vegetative B. anthracis, the effect of linezolid and ciprofloxacin on toxin production is of interest. The effect of simulated clinical regimens of ciprofloxacin and linezolid on the vegetative and spore populations and on toxin production was examined in an in vitro pharmacodynamic model over 15 days by using the toxin-producing Sterne strain of B. anthracis. Ciprofloxacin and linezolid reduced the total Sterne population at similar rates. With ciprofloxacin therapy, the total Sterne population consisted of spores. With linezolid therapy, >90% of the population was vegetative B. anthracis. With ciprofloxacin therapy, toxin was first detectable at 3 h and remained detectable for at least 5 h. Toxin was never detected with linezolid therapy. Ciprofloxacin and linezolid reduced the total Sterne population at similar rates. However, the B. anthracis population was primarily spores with ciprofloxacin therapy and was primarily vegetative bacteria with linezolid therapy. Toxin production was detected for at least 5 h with ciprofloxacin therapy but was never detected with linezolid treatment. Linezolid may have an advantage over ciprofloxacin for the treatment of B. anthracis infections.

show abstract

“…Samples obtained from each treatment arm were stored at Ϫ80°C until they were assayed for their linezolid concentrations. Linezolid concentrations in MHB were measured by high-performance liquid chromatography using the methods described by Li et al (20). The standard curve ranged from 0.1 mg/liter to 30 mg/liter.…”

Section: Methodsmentioning

confidence: 99%

Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis

Louie

Heine

Kim

et al. 2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Simulating the average non-protein-bound (free) human serum drug concentration-time profiles for linezolid in an in vitro pharmacodynamic model, we characterized the pharmacodynamic parameter(s) of linezolid predictive of kill and for prevention of resistance in Bacillus anthracis. In 10-day dose-ranging studies, the average exposure for >700 mg of linezolid given once daily (QD) resulted in >3-log CFU/ml declines in B. anthracis without resistance selection. Linezolid at <600 mg QD amplified for resistance. With twice-daily (q12h) dosing, linezolid at >500 mg q12 h was required for resistance prevention. In dose fractionation studies, killing of B. anthracis was predicted by the area under the time-concentration curve (AUC)/MIC ratio. However, resistance prevention was linked to the maximum serum drug concentration (C max )/MIC ratio. Monte Carlo simulations predicted that linezolid at 1,100 mg QD would produce in 96.7% of human subjects a free 24-h AUC that would match or exceed the average 24-h AUC of 78.5 mg ⅐ h/liter generated by linezolid at 700 mg QD while reproducing the shape of the concentration-time profile for this pharmacodynamically optimized regimen. However, linezolid at 700 mg q12h (cumulative daily dose of 1,400 mg) would produce an exposure that would equal or exceed the average free 24-h AUC of 90 mg ⅐ h/liter generated by linezolid at 500 mg q12h in 93.8% of human subjects. In conclusion, in our in vitro studies, the QD-administered, pharmacodynamically optimized regimen for linezolid killed drug-susceptible B. anthracis and prevented resistance emergence at lower dosages than q12h regimens. The lower dosage for the pharmacodynamically optimized regimen may decrease drug toxicity. Also, the QD administration schedule may improve patient compliance.

show abstract

Simple method for the assay of linezolid in Brain Heart Infusion broth by high‐performance liquid chromatography

Cited by 14 publications

References 29 publications

Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction

Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction

Differential Effects of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis in an In Vitro Pharmacodynamic System

Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis

Contact Info

Product

Resources

About